mTOR and cancer: insights into a complex relationship

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216 · see citing works

Upstream and downstream of mTOR

Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181 · see citing works

TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival

Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914 · see citing works

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083 · see citing works

mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery

Kim, D., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,974 · see citing works

Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton

Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665 · see citing works

Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB

Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,645 · see citing works

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · see citing works

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,097 · see citing works

Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control

Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886 · see citing works

Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action

Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Sujuti, H., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,810 · see citing works

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

Guba, M. O., von Breitenbuch, P., Steinbauer, M. G. M., Koehl, G. E., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S. A., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739 · see citing works

Growing roles for the mTOR pathway

Sarbassov, D. D., Ali, S. M., & Sabatini, D. M. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.09.009 · Cited by 1,556 · see citing works

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555 · see citing works

The coordinate regulation of the p53 and mTOR pathways in cells

Feng, Z., Zhang, H., Levine, A. J., & Jin, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502857102 · Cited by 1,235 · see citing works

Tuberous Sclerosis Complex Gene Products, Tuberin and Hamartin, Control mTOR Signaling by Acting as a GTPase-Activating Protein Complex toward Rheb

Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C., & Blenis, J. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00506-2 · Cited by 1,211 · see citing works

Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin

Hudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186 · see citing works

A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling

Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174 · see citing works

The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins

Harrington, L. S., Findlay, G. M., Gray, A., Толкачева, Т. А., Wigfield, S., Rebholz, H., Barnett, J., Leslie, N. R., Cheng, S., Shepherd, P. R., et al. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200403069 · Cited by 1,123 · see citing works

The LKB1 tumor suppressor negatively regulates mTOR signaling

Shaw, R. J., Bardeesy, N. M., Manning, B. D., Lopez, L. V., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,068 · see citing works

Insulin Activation of Rheb, a Mediator of mTOR/S6K/4E-BP Signaling, Is Inhibited by TSC1 and 2

Garami, A., Zwartkruis, F. J. T., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., Kozma, S. C., Hafen, E., Bos, J. L., & Thomas, G. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00220-x · Cited by 1,043 · see citing works

Role of Akt Signaling in Vascular Homeostasis and Angiogenesis

Shiojima, I., & Walsh, K. (2002) · Circulation Research · doi:10.1161/01.res.0000022200.71892.9f · Cited by 1,011 · see citing works

Rheb Binds and Regulates the mTOR Kinase

Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K., & Avruch, J. (2005) · Current Biology · doi:10.1016/j.cub.2005.02.053 · Cited by 1,005 · see citing works

Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients

Stallone, G., Schena, A., Infante, B., Paolo, S. D., Loverre, A., Maggio, G., Ranieri, E., Gesualdo, L., Schena, F. P., & Grandaliano, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042831 · Cited by 982 · see citing works

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B. L., THOMAS, G. V., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 968 · see citing works

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964 · see citing works

Akt regulates growth by directly phosphorylating Tsc2

Potter, C. J., Pedraza, L. G., & Xu, T. (2002) · Nature Cell Biology · doi:10.1038/ncb840 · Cited by 959 · see citing works

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

Wendel, H., de Stanchina, E., Fridman, J. S., Malina, A., Ray, S., Kogan, S. C., Cordon‐Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 956 · see citing works

GβL, a Positive Regulator of the Rapamycin-Sensitive Pathway Required for the Nutrient-Sensitive Interaction between Raptor and mTOR

Kim, D., Sarbassov, D. D., Ali, S. M., Latek, R. R., Guntur, K., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00114-x · Cited by 955 · see citing works

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Atkins, M. B., Hidalgo, M. M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S.-H., Marshall, B., Boni, J. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.185 · Cited by 942 · see citing works

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

Zhang, Y., Gao, X., Saucedo, L. J., Ru, B., Edgar, B. A., & Pan, D. (2003) · Nature Cell Biology · doi:10.1038/ncb999 · Cited by 924 · see citing works

Inappropriate Activation of the TSC/Rheb/mTOR/S6K Cassette Induces IRS1/2 Depletion, Insulin Resistance, and Cell Survival Deficiencies

Shah, O. J., Wang, Z., & Hunter, T. R. (2004) · Current Biology · doi:10.1016/j.cub.2004.08.026 · Cited by 800 · see citing works

Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition

Sun, S., Rosenberg, L. M., Wang, X., Zhou, Z., Yue, P., Fu, H., & Khuri, F. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0917 · Cited by 800 · see citing works

Tsc tumour suppressor proteins antagonize amino-acid–TOR signalling

Gao, X., Zhang, Y., Arrazola, P., Hino, O., Kobayashi, T., Yeung, R. S., Ru, B., & Pan, D. (2002) · Nature Cell Biology · doi:10.1038/ncb847 · Cited by 719 · see citing works

mSin1 Is Necessary for Akt/PKB Phosphorylation, and Its Isoforms Define Three Distinct mTORC2s

Frías, M. A., Thoreen, C. C., Jaffe, J. D., Schroder, W. A., Sculley, T. B., Carr, S. A., & Sabatini, D. M. (2006) · Current Biology · doi:10.1016/j.cub.2006.08.001 · Cited by 690 · see citing works

Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K. V., Boni, J. P., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 690 · see citing works

The Mammalian Target of Rapamycin (mTOR) Partner, Raptor, Binds the mTOR Substrates p70 S6 Kinase and 4E-BP1 through Their TOR Signaling (TOS) Motif

Nojima, H., Tokunaga, C., Eguchi, S., Oshiro, N., Sujuti, H., Yoshino, K., Hara, K., Tanaka, N., Avruch, J., & Yonezawa, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200665200 · Cited by 678 · see citing works

Rheb promotes cell growth as a component of the insulin/TOR signalling network

Saucedo, L. J., Gao, X., Chiarelli, D. A., Li, L., Pan, D., & Edgar, B. A. (2003) · Nature Cell Biology · doi:10.1038/ncb996 · Cited by 658 · see citing works

mTOR·RICTOR Is the Ser473 Kinase for Akt/Protein Kinase B in 3T3-L1 Adipocytes

Hresko, R. C., & Mueckler, M. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508361200 · Cited by 631 · see citing works

mTOR Is Essential for Growth and Proliferation in Early Mouse Embryos and Embryonic Stem Cells

Murakami, M., Ichisaka, T., Maeda, M., Oshiro, N., Hara, K., Edenhofer, F., Kiyama, H., Yonezawa, K., & Yamanaka, S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6710-6718.2004 · Cited by 620 · see citing works

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

Franz, D. N., Leonard, J. M., Tudor, C., Chuck, G., Caré, M. M., Sethuraman, G., Dinopoulos, A., Thomas, G., & Crone, K. R. (2006) · Annals of Neurology · doi:10.1002/ana.20784 · Cited by 614 · see citing works

The NF1 tumor suppressor critically regulates TSC2 and mTOR

Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503224102 · Cited by 605 · see citing works

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604 · see citing works

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

Fan, Q.-W., Knight, Z. A., Goldenberg, D., Yu, W., Mostov, K. E., Stokoe, D., Shokat, K. M., & Weiss, W. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.029 · Cited by 584 · see citing works

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten +/− mice

Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M. S., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 568 · see citing works

Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndromePreprint

Corradetti, M. N., Inoki, K., Bardeesy, N. M., DePinho, R. A., & Guan, K. (2004) · Genes & Development · doi:10.1101/gad.1199104 · Cited by 556 · see citing works

The Drosophila Tuberous Sclerosis Complex Gene Homologs Restrict Cell Growth and Cell Proliferation

Tapon, N., Ito, N., Dickson, B. J., Treisman, J. E., & Hariharan, I. K. (2001) · Cell · doi:10.1016/s0092-8674(01)00332-4 · Cited by 542 · see citing works

Amino Acid and Insulin Signaling via the mTOR/p70 S6 Kinase Pathway

Tremblay, F., & Marette, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106703200 · Cited by 536 · see citing works

Rheb is an essential regulator of S6K in controlling cell growth in Drosophila

Stocker, H., Radimerski, T., Schindelholz, B., Wittwer, F., Belawat, P., Daram, P., Breuer, S., Thomas, G., & Hafen, E. (2003) · Nature Cell Biology · doi:10.1038/ncb995 · Cited by 530 · see citing works

An expanding role for mTOR in cancer

Guertin, D. A., & Sabatini, D. M. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.06.007 · Cited by 519 · see citing works

TOS Motif-Mediated Raptor Binding Regulates 4E-BP1 Multisite Phosphorylation and Function

Schalm, S. S., Fingar, D. C., Sabatini, D. M., & Blenis, J. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00329-4 · Cited by 513 · see citing works

Cyclin D Expression Is Controlled Post-transcriptionally via a Phosphatidylinositol 3-Kinase/Akt-dependent Pathway

Muise‐Helmericks, R. C., Grimes, H. L., Bellacosa, A., Malstrom, S. E., Tsichlis, P. N., & Rosen, N. X. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.45.29864 · Cited by 511 · see citing works

Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma

Witzig, T. E., Geyer, S. M., Ghobrial, I. M., Inwards, D. J., Fonseca, R., Kurtin, P. J., Ansell, S. M., Luyun, R. F., Flynn, P. J., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.466 · Cited by 510 · see citing works

Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2

Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J., & Sabatini, B. L. (2005) · Nature Neuroscience · doi:10.1038/nn1566 · Cited by 497 · see citing works

Disruption of the Mouse mTOR Gene Leads to Early Postimplantation Lethality and Prohibits Embryonic Stem Cell Development

Gangloff, Y.-G., Mueller, M., Dann, S. G., Svoboda, P., Sticker, M., Spetz, J.-F., Um, S. H., Brown, E. J., Cereghini, S., Thomas, G., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9508-9516.2004 · Cited by 485 · see citing works

The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation

Beuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O’Reilly, T., Natt, F., Hall, J., Lane, H. A., & Thomas, G. (2005) · Cell · doi:10.1016/j.cell.2004.12.040 · Cited by 484 · see citing works

Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer

Chan, S. Y. T., Scheulen, M. E., Johnston, S. R. D., Mross, K. B., Cardoso, F., Dittrich, C., EIERMANN, W., Hess, D., Morant, R., Семиглазов, В. Ф., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.66.130 · Cited by 468 · see citing works

Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation

Foukas, L. C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A. J. H., Withers, D. J., & Vanhaesebroeck, B. (2006) · Nature · doi:10.1038/nature04694 · Cited by 463 · see citing works

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin

Phung, T. L., Ziv, K., Dabydeen, D. A., Eyiah-Mensah, G., Riveros, M., Perruzzi, C. A., Sun, J., Monahan-Earley, R. A., Shiojima, I., Nagy, J. A., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.003 · Cited by 439 · see citing works

A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1.

Haruta, T., Uno, T., Kawahara, J., Takano, A., Egawa, K., Sharma, P. M., Olefsky, J., & Kobayashi, M. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.6.0446 · Cited by 437 · see citing works

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

Chang, S. M., Wen, P. Y., Cloughesy, T. F., Greenberg, H. S., Schiff, D., Conrad, C. A., Fink, K., Robins, H. I., DeAngelis, L. M., Raizer, J. J., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1444-0 · Cited by 396 · see citing works

Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes

Montaner, S., Sodhi, A., Molinolo, A. A., Bugge, T. H., Sawai, E. T., Yunsheng, H., Li, Y., Ray, P. E., & Gutkind, J. S. (2003) · Cancer Cell · doi:10.1016/s1535-6108(02)00237-4 · Cited by 372 · see citing works

Activity of rapamycin (AY-22,989) against transplanted tumors.

Eng, C. P., Sehgal, S. N., & Vézina, C. (1984) · The Journal of Antibiotics · doi:10.7164/antibiotics.37.1231 · Cited by 354 · see citing works

Rapamycin Inhibition of the G1 to S Transition Is Mediated by Effects on Cyclin D1 mRNA and Protein Stability

Hashemolhosseini, S., Nagamine, Y., Morley, S., Desrivières, S., Merćep, L., & Ferrari, S. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14424 · Cited by 343 · see citing works

The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho

Lamb, R. F., Roy, C., Diefenbach, T. J., Vinters, H. V., Johnson, M. W., Jay, D. G., & Hall, A. (2000) · Nature Cell Biology · doi:10.1038/35010550 · Cited by 326 · see citing works

Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus

Bufalo, D. D., Ciuffreda, L., Trisciuoglio, D., Desideri, M., Cognetti, F., Zupi, G., & Milella, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2825 · Cited by 318 · see citing works

G 1 cell cycle progression and the expression of G 1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells

Gao, N., Flynn, D. C., Zhang, Z., Zhong, X., Walker, V. E., Liu, K. J., Shi, X., & Jiang, B. (2004) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00422.2003 · Cited by 309 · see citing works

Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma

Rudelius, M., Pittaluga, S., Nishizuka, S., Pham, T. H.-T., Fend, F., Jaffe, E. S., Quintanilla‐Martínez, L., & Raffeld, M. A. (2006) · Blood · doi:10.1182/blood-2006-04-015586 · Cited by 275 · see citing works

Conversion to sirolimus: a successful treatment for posttransplantation Kaposi???s sarcoma12

Campistol, J. M., Gutiérrez-Dalmau, Á., & Torregrosa, J. (2004) · Transplantation · doi:10.1097/01.tp.0000115344.18025.0b · Cited by 261 · see citing works

Mammalian Target of Rapamycin Pathway Regulates Insulin Signaling via Subcellular Redistribution of Insulin Receptor Substrate 1 and Integrates Nutritional Signals and Metabolic Signals of Insulin

Takano, A., Usui, I., Haruta, T., Kawahara, J., Uno, T., Iwata, M., & Kobayashi, M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.15.5050-5062.2001 · Cited by 249 · see citing works

Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2Preprint

Manning, B. D., Logsdon, M. N., Lipovsky, A. I., Abbott, D. W., Kwiatkowski, D. J., & Cantley, L. C. (2005) · Genes & Development · doi:10.1101/gad.1314605 · Cited by 236 · see citing works

Inactivation of the Tuberous Sclerosis Complex-1 and -2 Gene Products Occurs by Phosphoinositide 3-Kinase/Akt-dependent and -independent Phosphorylation of Tuberin

Tee, A. R., Anjum, R., & Blenis, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303257200 · Cited by 217 · see citing works

The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL

Teachey, D. T., Obzut, D. A., Cooperman, J., Fang, J., Carroll, M. P., Choi, J. K., Houghton, P. J., Brown, V. I., & Grupp, S. A. (2005) · Blood · doi:10.1182/blood-2005-05-1935 · Cited by 166 · see citing works

Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells

Avellino, R., Romano, S., Parasole, R., Bisogni, R., Lamberti, A., Poggi, V., Venuta, S., & Romano, M. F. (2005) · Blood · doi:10.1182/blood-2005-03-0929 · Cited by 151 · see citing works

FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line

Albers, M. W., Williams, R. T., Brown, E. J., Tanaka, A., Hall, F. L., & Schreiber, S. L. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41602-x · Cited by 145 · see citing works

Novel Role of the Small GTPase Rheb: Its Implication in Endocytic Pathway Independent of the Activation of Mammalian Target of Rapamycin

Saito, K. (2005) · The Journal of Biochemistry · doi:10.1093/jb/mvi046 · Cited by 128 · see citing works

Rapamycin-Induced Endothelial Cell Death and Tumor Vessel Thrombosis Potentiate Cytotoxic Therapy against Pancreatic Cancer

Bruns, C. J., Koehl, G. E., Guba, M. O., Yezhelyev, M., Steinbauer, M. G. M., Seeliger, H., Schwend, A., Hoehn, A., Jauch, K., & Geissler, E. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0502 · Cited by 115 · see citing works

Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppressionPreprint

Ma, L., Teruya‐Feldstein, J., Behrendt, N., Chen, Z., Noda, T., Hino, O., Cordon‐Cardo, C., & Pandolfi, P. P. (2005) · Genes & Development · doi:10.1101/gad.1314405 · Cited by 112 · see citing works

Regulation of B-Raf Kinase Activity by Tuberin and Rheb Is Mammalian Target of Rapamycin (mTOR)-independent

Karbowniczek, M., Cash, T. P., Cheung, M., Robertson, G. P., Astrinidis, A., & Henske, E. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402591200 · Cited by 99 · see citing works

Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells

Treeck, O., Wackwitz, B., Haus, U., & Ortmann, O. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.019 · Cited by 96 · see citing works

Rheb Interacts with Raf-1 Kinase and May Function To Integrate Growth Factor- and Protein Kinase A-Dependent Signals

Yee, W. M., & Worley, P. F. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.2.921 · Cited by 86 · see citing works

Mutations in the PI3K/PTEN/TSC2 Pathway Contribute to Mammalian Target of Rapamycin Activity and Increased Translation under Hypoxic Conditions

Kaper, F., Dornhöfer, N., & Giaccia, A. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3375 · Cited by 85 · see citing works

Rheb Inhibits C-Raf Activity and B-Raf/C-Raf Heterodimerization

Karbowniczek, M., Robertson, G. P., & Henske, E. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605273200 · Cited by 83 · see citing works

Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis

Fumarola, C., Monica, S. L., Alfieri, R. R., Borra, E., & Guidotti, G. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401660 · Cited by 80 · see citing works

Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.

Thimmaiah, K. N., Easton, J. B., Huang, S., Veverka, K. A., Germain, G. S., Harwood, F. C., & Houghton, P. J. (2003) · PubMed · Cited by 73 · see citing works

Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells.

Hipp, S., Ringshausen, I., Oelsner, M., Bogner, C., Peschel, C., & Decker, T. W. (2005) · PubMed · Cited by 68 · see citing works

Rapamycin Disrupts Cyclin/Cyclin-Dependent Kinase/p21/Proliferating Cell Nuclear Antigen Complexes and Cyclin D1 Reverses Rapamycin Action by Stabilizing These Complexes

Law, M. E., Forrester, E., Chytil, A. M., Corsino, P. E., Green, G., Davis, B. J., Rowe, T. C., & Law, B. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1672 · Cited by 66 · see citing works

Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways

Hahn, M., Li, W., Yu, C., Rahmani, M., Dent, P., & Grant, S. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0137 · Cited by 63 · see citing works

Regulation of Microtubule-Dependent Protein Transport by the TSC2/Mammalian Target of Rapamycin Pathway

Jiang, X., & Yeung, R. S. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4510 · Cited by 50 · see citing works

Biology and therapy of mantle cell lymphoma

Williams, M. E., & Densmore, J. J. (2005) · Current Opinion in Oncology · doi:10.1097/01.cco.0000174039.69656.2b · Cited by 45 · see citing works

Identification and Characterization of RHEBL1, a Novel Member of Ras Family, which Activates Transcriptional Activities of NF-Kappa B

Yuan, J., Shan, Y., Chen, X., Tang, W., Luo, K., Ni, J., Wan, B., & Yu, L. (2005) · Molecular Biology Reports · doi:10.1007/s11033-005-0984-x · Cited by 32 · see citing works

Tuberous sclerosis genes regulate cellular 14-3-3 protein levels

Hengstschläger, M., Rosner, M., Fountoulakis, M., & Lübec, G. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.10.170 · Cited by 27 · see citing works

Targeted Inhibition of Angiogenic Factors in AIDS-related Disorders

Aoki, Y., & Tosato, G. (2003) · Current Drug Targets - Infectious Disorders · doi:10.2174/1568005033481222 · Cited by 25 · see citing works

AKT/PKB signaling: navigating downstream

Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115 · see citing works

Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy

Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D. A., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,154 · see citing works

AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint

Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849 · see citing works

Autophagy: cellular and molecular mechanisms

Glick, D. R., Barth, S., & Macleod, K. F. (2010) · The Journal of Pathology · doi:10.1002/path.2697 · Cited by 3,815 · see citing works

Targeting the phosphoinositide 3-kinase pathway in cancer

Liu, P., Cheng, H.-L. M., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,722 · see citing works

SUnSET, a nonradioactive method to monitor protein synthesis

Schmidt, E. K., Clavarino, G., Ceppi, M., & Pierre, P. (2009) · Nature Methods · doi:10.1038/nmeth.1314 · Cited by 1,706 · see citing works

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803 · see citing works

Renal cell carcinoma

Rini, B. I., Campbell, S. C., & Escudier, B. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60229-4 · Cited by 1,634 · see citing works

Cyclin D as a therapeutic target in cancer

Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370 · see citing works

p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling

Budanov, A. V., & Karin, M. (2008) · Cell · doi:10.1016/j.cell.2008.06.028 · Cited by 1,326 · see citing works

Systemic Therapy for Metastatic Renal-Cell Carcinoma

Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,287 · see citing works

mTOR differentially regulates effector and regulatory T cell lineage commitment

Delgoffe, G. M., Kole, T., Zheng, Y., Zarek, P. E., Matthews, K., Xiao, B., Worley, P., Kozma, S., & Powell, J. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.014 · Cited by 1,293 · see citing works

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236 · see citing works

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202 · see citing works

Autophagy mediates the mitotic senescence transition

Young, A. R. J., Narita, M., Ferreira, M., Kirschner, K., Sadaie, M., Darot, J. F. J., Tavaré, S., Arakawa, S., Shimizu, S., Watt, F. M., et al. (2009) · Genes & Development · doi:10.1101/gad.519709 · Cited by 1,078 · see citing works

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,080 · see citing works

A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1

Bar-Peled, L., Chantranupong, L., Cherniack, A. D., Chen, W. W., Ottina, K. A., Grabiner, B. C., Spear, E. D., Carter, S. L., Meyerson, M., & Sabatini, D. M. (2013) · Science · doi:10.1126/science.1232044 · Cited by 1,080 · see citing works

Targeting the PI3K pathway in cancer: are we making headway?

Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033 · see citing works

Potential therapeutic applications of autophagy

Rubinsztein, D. C., Gestwicki, J. E., Murphy, L. O., & Klionsky, D. J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2272 · Cited by 1,004 · see citing works

Molecular targeted therapies in hepatocellular carcinoma†

Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 999 · see citing works

The common biology of cancer and ageing

Finkel, T., Serrano, M., & Blasco, M. A. (2007) · Nature · doi:10.1038/nature05985 · Cited by 988 · see citing works

Translational control of long-lasting synaptic plasticity and memory

Costa-Mattioli, M., Sossin, W. S., Klann, E., & Sonenberg, N. (2009) · Neuron · doi:10.1016/j.neuron.2008.10.055 · Cited by 944 · see citing works

BAP1 loss defines a new class of renal cell carcinoma

Peña‐Llopis, S., Vega-Rubín-de-Celis, S., Liao, A. K., Leng, N., Pavía-Jiménez, A., Wang, S., Yamasaki, T., Zhrebker, L., Sivanand, S., Spence, P., et al. (2012) · Nature Genetics · doi:10.1038/ng.2323 · Cited by 963 · see citing works

Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner

Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889 · see citing works

T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR

Sauer, S., Bruno, L., Hertweck, A., Finlay, D. K., Leleu, M., Spivakov, M., Knight, Z. A., Cobb, B. S., Cantrell, D. A., O’Connor, E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800928105 · Cited by 861 · see citing works

Tuberous sclerosis complex

Henske, E. P., Jóźwiak, S., Kingswood, J. C., Sampson, J. R., & Thiele, E. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.35 · Cited by 856 · see citing works

Immunoregulatory functions of mTOR inhibition

Thomson, A. W., Turnquist, H. R., & Raimondi, G. (2009) · Nature reviews. Immunology · doi:10.1038/nri2546 · Cited by 849 · see citing works

Regulation of Immune Responses by mTOR

Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836 · see citing works

Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium

Høyer-Hansen, M. H., & Jäättelä, M. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402200 · Cited by 765 · see citing works

The AKT–mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells

Haxhinasto, S., Mathis, D., & Benoist, C. (2008) · Journal of Experimental Medicine · doi:10.1084/jem.20071477 · Cited by 775 · see citing works

Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis

Li, S., Brown, M. S., & Goldstein, J. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914798107 · Cited by 733 · see citing works

mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs

Dowling, R. J. O., Topisirović, I., Alain, T., Bidinosti, M., Fonseca, B. D., Petroulakis, E., Wang, X., Larsson, O. S., Selvaraj, A., Liu, Y., et al. (2010) · Science · doi:10.1126/science.1187532 · Cited by 726 · see citing works

Metabolic targets for cancer therapy

Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 705 · see citing works

Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells

Yuneva, M., Zamboni, N., Oefner, P., Sachidanandam, R., & Lazebnik, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200703099 · Cited by 690 · see citing works

The natural history of epilepsy in tuberous sclerosis complex

Chu, C. J., Major, P., Camposano, S. E., Muzykewicz, D. A., & Thiele, E. A. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02474.x · Cited by 638 · see citing works

Biological response of cancer cells to radiation treatment

Baskar, R., Dai, J., Nei, W. L., Yeo, R., & Yeoh, K. (2014) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2014.00024 · Cited by 638 · see citing works

Akt-dependent regulation of NF-κB is controlled by mTOR and Raptor in association with IKKPreprint

Dan, H. C., Cooper, M. J., Cogswell, P. C., Duncan, J. A., Ting, J. P.-Y., & Baldwin, A. S. (2008) · Genes & Development · doi:10.1101/gad.1662308 · Cited by 638 · see citing works

Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling

Ikenoue, T., Inoki, K., Yang, Q., Zhou, X., & Guan, K. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.119 · Cited by 605 · see citing works

The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development

Morrison, D. K. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.10.003 · Cited by 604 · see citing works

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593 · see citing works

Dysregulation of mTOR signaling in fragile X syndrome

Sharma, A., Hoeffer, C. A., Takayasu, Y., Miyawaki, T., McBride, S. M., Klann, E., & Zukin, R. S. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3696-09.2010 · Cited by 557 · see citing works

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

Tabernero, J. M., Rojo, F., Calvo, E., Burris, H. A., Judson, I. R., Hazell, K., Martinelli, E., y Cajal, S. R., Jones, S. F., Vidal, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5482 · Cited by 537 · see citing works

Signalling to translation: How signal transduction pathways control the protein synthetic machinery

Proud, C. G. (2007) · Biochemical Journal · doi:10.1042/bj20070024 · Cited by 520 · see citing works

Advances in targeted therapy for esophageal cancer

Yang, Y., Hong, P., Xu, W. W., He, Q., & Li, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00323-3 · Cited by 509 · see citing works

p62 Is a Key Regulator of Nutrient Sensing in the mTORC1 Pathway

Durán, Á., Amanchy, R., Linares, J. F., Joshi, J. P., Abu‐Baker, S., Porollo, A., Hansen, M., Moscat, J., & Díaz-Meco, M. T. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.06.038 · Cited by 502 · see citing works

Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function

Meikle, L. M., Pollizzi, K. N., Egnor, A., Kramvis, I., Lane, H. A., Şahin, M., & Kwiatkowski, D. J. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0955-08.2008 · Cited by 500 · see citing works

Melanoma: from mutations to medicine

Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496 · see citing works

The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism

Powell, J. D., & Delgoffe, G. M. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.002 · Cited by 487 · see citing works

mTOR: Role in cancer, metastasis and drug resistance

Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.003 · Cited by 483 · see citing works

Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells

Ouyang, W., Beckett, O. R., Ma, Q., Paik, J.-H., DePinho, R. A., & Li, M. O. (2010) · Nature Immunology · doi:10.1038/ni.1884 · Cited by 467 · see citing works

Dissecting the role of mTOR: Lessons from mTOR inhibitors

Dowling, R. J. O., Topisirović, I., Fonseca, B. D., & Sonenberg, N. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.001 · Cited by 459 · see citing works

Probing cellular protein complexes using single-molecule pull-down

Jain, A., Liu, R., Ramani, B., Arauz, E. J., Ishitsuka, Y., Ragunathan, K., Park, J., Chen, J., Xiang, Y. K., & Ha, T. (2011) · Nature · doi:10.1038/nature10016 · Cited by 429 · see citing works

Healthy Effects of Plant Polyphenols: Molecular Mechanisms

Leri, M., Scuto, M. C., Ontario, M. L., Calabrese, V., Calabrese, E. J., Bucciantini, M., & Stefani, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041250 · Cited by 440 · see citing works

Epigenetic-Mediated Dysfunction of the Bone Morphogenetic Protein Pathway Inhibits Differentiation of Glioblastoma-Initiating Cells

Lee, J., Son, M. J., Woolard, K., Donin, N. M., Li, A., Cheng, C. H., Kotliarova, S. E., Kotliarov, Y., Walling, J., Ahn, S. J., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.005 · Cited by 429 · see citing works

Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy

Maycotte, P., Aryal, S., Cummings, C. T., Thorburn, J., Morgan, M. J., & Thorburn, A. M. (2012) · Autophagy · doi:10.4161/auto.8.2.18554 · Cited by 401 · see citing works

Phospholipase D: Enzymology, Functionality, and Chemical Modulation

Selvy, P. E., Lavieri, R. R., Lindsley, C. W., & Brown, H. A. (2011) · Chemical Reviews · doi:10.1021/cr200296t · Cited by 392 · see citing works

Genomic landscapes of Chinese hamster ovary cell lines as revealed by the Cricetulus griseus draft genome

Lewis, N. E., Liu, X., Li, Y., Nagarajan, H., Yerganian, G., O'Brien, E., Bordbar, A., Roth, A. M., Rosenbloom, J., Bian, C., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2624 · Cited by 380 · see citing works

A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis

Alimonti, A., Nardella, C., Chen, Z., Clohessy, J. G., Carracedo, A., Trotman, L. C., Cheng, K., Varmeh, S., Kozma, S. C., Thomas, G., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40535 · Cited by 374 · see citing works

mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging

Castilho, R. M., Squarize, C. H., Chodosh, L. A., Williams, B. O., & Gutkind, J. S. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.06.017 · Cited by 371 · see citing works

Vascular Smooth Muscle Cell Proliferation in Restenosis

Marx, S. O., Totary-Jain, H., & Marks, A. R. (2011) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.110.957332 · Cited by 350 · see citing works

GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer

Scott, K. L., Kabbarah, O., Liang, M., Ivanova, E. V., Anagnostou, V., Wu, J., Dhakal, S., Wu, M., Chen, S., Feinberg, T. Y., et al. (2009) · Nature · doi:10.1038/nature08109 · Cited by 350 · see citing works

Making synaptic plasticity and memory last: mechanisms of translational regulationPreprint

Richter, J. D., & Klann, E. (2009) · Genes & Development · doi:10.1101/gad.1735809 · Cited by 345 · see citing works

Physiological regulation of Akt activity and stability.

Liao, Y., & Hung, M. (2010) · PubMed Central · Cited by 343 · see citing works

Regulation of mTORC1 and mTORC2 Complex Assembly by Phosphatidic Acid: Competition with Rapamycin

Toschi, A., Lee, E., Xu, L., Garcia, A., Gadir, N., & Foster, D. A. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00782-08 · Cited by 334 · see citing works

Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models.

Hebron, M., Lonskaya, I., & Moussa, C. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt192 · Cited by 319 · see citing works

Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes

Shivaswamy, V., Boerner, B., & Larsen, J. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1084 · Cited by 328 · see citing works

Targeting the mTOR signaling network in cancer

Chiang, G. G., & Abraham, R. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.08.001 · Cited by 328 · see citing works

Targeting SREBP-1-driven Lipid Metabolism to Treat Cancer

Guo, D., Bell, E. H., Mischel, P. S., & Chakravarti, A. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990486 · Cited by 328 · see citing works

Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance

Wang, R.-H., Kim, H., Xiao, C., Xu, X., Gavrilova, O., & Deng, C. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46243 · Cited by 311 · see citing works

S6K1 Regulates GSK3 under Conditions of mTOR-Dependent Feedback Inhibition of Akt

Zhang, H. H., Lipovsky, A. I., Dibble, C. C., Şahin, M., & Manning, B. D. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.09.019 · Cited by 309 · see citing works

NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth

James, M. F., Han, S., Polizzano, C., Plotkin, S. R., Manning, B. D., Stemmer-Rachamimov, A. O., Gusella, J. F., & Ramesh, V. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01581-08 · Cited by 307 · see citing works

Novel Agents on the Horizon for Cancer Therapy

Ma, W. W., & Adjei, A. A. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20003 · Cited by 303 · see citing works

Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2

Toschi, A., Lee, E., Gadir, N., Ohh, M., & Foster, D. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c800170200 · Cited by 301 · see citing works

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

Wolpin, B. M., Hezel, A. F., Abrams, T., Blaszkowsky, L. S., Meyerhardt, J. A., Chan, J. A., Enzinger, P. C., Allen, B., Clark, J. W., Ryan, D. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9514 · Cited by 297 · see citing works

mTOR inhibitors in cancer therapy

Zaytseva, Y. Y., Valentino, J. D., Gulhati, P., & Evers, B. M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.005 · Cited by 292 · see citing works

The AMPK Inhibitor Compound C Is a Potent AMPK-Independent Antiglioma Agent

Liu, X., Chhipa, R. R., Nakano, I., & Dasgupta, B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0579 · Cited by 288 · see citing works

PTEN/mTOR and axon regeneration

Park, K. K., Liu, K., Hu, Y., Kanter, J. L., & He, Z. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.12.032 · Cited by 285 · see citing works

Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia

Chan, S. M., Weng, A. P., Tibshirani, R. J., Aster, J. C., & Utz, P. J. (2007) · Blood · doi:10.1182/blood-2006-08-039883 · Cited by 281 · see citing works

Anergic T Cells Are Metabolically Anergic

Zheng, Y., Delgoffe, G. M., Meyer, C. F., Chan, W., & Powell, J. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803510 · Cited by 280 · see citing works

NFκB signaling in carcinogenesis and as a potential molecular target for cancer therapy

Shen, H., & Tergaonkar, V. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0315-0 · Cited by 278 · see citing works

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies

Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., et al. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160867 · Cited by 265 · see citing works

The PKB/AKT Pathway in Cancer

Carnero, A. (2009) · Current Pharmaceutical Design · doi:10.2174/138161210789941865 · Cited by 271 · see citing works

DEPTOR, an mTOR Inhibitor, Is a Physiological Substrate of SCFβTrCP E3 Ubiquitin Ligase and Regulates Survival and Autophagy

Zhao, Y., Xiong, X., & Sun, Y. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.029 · Cited by 270 · see citing works

Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies

Keppler‐Noreuil, K. M., Parker, V. E. R., Darling, T. N., & Martinez‐Agosto, J. A. (2016) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31531 · Cited by 270 · see citing works

Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship

Jhanwar-Uniyal, M., Wainwright, J. V., Mohan, A. L., Tobias, M. E., Murali, R., Gandhi, C. D., & Schmidt, M. H. (2019) · Advances in Biological Regulation · doi:10.1016/j.jbior.2019.03.003 · Cited by 268 · see citing works

Trial watch

Vacchelli, E., Senovilla, L., Eggermont, A. M. M., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23510 · Cited by 265 · see citing works

Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1 α

McInturff, A. M., Cody, M. J., Elliott, E. A., Glenn, J. W., Rowley, J. W., Rondina, M. T., & Yost, C. C. (2012) · Blood · doi:10.1182/blood-2012-01-405993 · Cited by 265 · see citing works

Therapeutic Targeting of Autophagy in Disease: Biology and Pharmacology

Cheng, Y., Ren, X., Hait, W. N., & Yang, J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007120 · Cited by 258 · see citing works

Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis

Liu, P., Gan, W., Inuzuka, H., Lazorchak, A. S., Gao, D., Arojo, O., Liu, D., Wan, L., Zhai, B., Yu, Y., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2860 · Cited by 256 · see citing works

Kidney-Targeted Birt-Hogg-Dube Gene Inactivation in a Mouse Model: Erk1/2 and Akt-mTOR Activation, Cell Hyperproliferation, and Polycystic Kidneys

Baba, M., Furihata, M., Hong, S.-B., Tessarollo, L., Haines, D. C., Southon, E. A., Patel, V., Igarashi, P., Alvord, W. G., Leighty, R. M., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm288 · Cited by 258 · see citing works

AMPK signaling and its targeting in cancer progression and treatment

Hsu, C.-C., Peng, D., Cai, Z., & Lin, H. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.006 · Cited by 257 · see citing works

mTORC2 Activity Is Elevated in Gliomas and Promotes Growth and Cell Motility via Overexpression of Rictor

Masri, J., Bernath, A., Martin, J., Jo, O. D., Vartanian, R., Funk, A., & Gera, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2223 · Cited by 253 · see citing works

Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function

Jastrzebski, K., Hannan, K. M., Tchoubrieva, E. B., Hannan, R. D., & Pearson, R. B. (2007) · Growth Factors · doi:10.1080/08977190701779101 · Cited by 240 · see citing works

mTOR Drives Its Own Activation via SCFβTrCP-Dependent Degradation of the mTOR Inhibitor DEPTOR

Gao, D., Inuzuka, H., Tan, M.-K. M., Fukushima, H., Locasale, J. W., Liu, P., Wan, L., Zhai, B., Chin, Y. R., Shaik, S., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.030 · Cited by 248 · see citing works

The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy

Abraham, R. T., & Gibbons, J. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2798 · Cited by 244 · see citing works

Nucleolus as an emerging hub in maintenance of genome stability and cancer pathogenesis

Lindström, M. S., Jurada, D., Bursać, S., Oršolić, I., Bártek, J., & Volarević, S. (2018) · Oncogene · doi:10.1038/s41388-017-0121-z · Cited by 233 · see citing works

Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2

Hasumi, Y., Baba, M., Ajima, R., Hasumi, H., Valera, V., Klein, M. E., Haines, D. C., Merino, M. J., Hong, S., Yamaguchi, T. P., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908853106 · Cited by 232 · see citing works

Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade

Ma, J., Meng, Y., Kwiatkowski, D. J., Chen, X., Peng, H., Sun, Q., Zha, X., Wang, F., Wang, Y., Jing, Y., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci37964 · Cited by 231 · see citing works

Targeting tumour-supportive cellular machineries in anticancer drug development

Dobbelstein, M., & Moll, U. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4201 · Cited by 229 · see citing works

Novel synthetic small‐molecule activators of AMPK as enhancers of autophagy and amyloid‐β peptide degradation

Vingtdeux, V., Chandakkar, P., Zhao, H., d’Abramo, C., Davies, P., & Marambaud, P. (2010) · The FASEB Journal · doi:10.1096/fj.10-167361 · Cited by 229 · see citing works

Drug discovery targeting the mTOR pathway

Martelli, A. M., Buontempo, F., & McCubrey, J. A. (2018) · Clinical Science · doi:10.1042/cs20171158 · Cited by 76 · see citing works

TOR (target of rapamycin) as an anti-cancer target

Bousquet, G., Dreyer, C., Faivre, S. J., & Raymond, É. (2007) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.04.004 · Cited by 2 · see citing works

Mammalian Target of Rapamycin (mTOR) Signalling Pathway-A Potential Target for Cancer Intervention: A Short Overview

Basnet, R., Basnet, B. B., Gupta, R., Basnet, T. B., Khadka, S., & Alam, M. S. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230331081959 · Cited by 11 · see citing works

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44145 · Cited by 427 · see citing works

Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies

Mehta, D., Rajput, K., Jain, D., Bajaj, A., & Dasgupta, U. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00530 · Cited by 22 · see citing works